Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Voyageur Pharmaceuticals ( (TSE:VM) ) has provided an announcement.
Voyageur Pharmaceuticals has issued 191,490 Deferred Share Units to its directors as part of its equity incentive compensation plan. This move is part of the company’s broader strategy to solidify its market presence and transition into a high-margin domestic manufacturer of radiology drugs. The company has completed clinical product testing with positive results and is in discussions with multinational radiology drug companies, indicating potential growth and expansion in the imaging contrast agent market.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian company specializing in the development of barium and iodine Active Pharmaceutical Ingredients (API) for high-performance and cost-effective imaging contrast agents. The company focuses on vertically integrating the barium and iodine contrast markets and aims to become a key player by producing its own barium and iodine. Voyageur is also pursuing the development of new endo fullerene drugs and is committed to sustainability and environmental stewardship, with plans to build carbon-capture infrastructure. The company owns a 100% interest in the Frances Creek barium sulphate project, which offers a rare and exceptional grade mineral for the pharmaceutical marketplace.
YTD Price Performance: 2.56%
Average Trading Volume: 26,921
Technical Sentiment Signal: Sell
Current Market Cap: $20.85M
For a thorough assessment of VM stock, go to TipRanks’ Stock Analysis page.